Nanostructured lipid carriers versus solid lipid nanoparticles for the potential treatment of pulmonary hypertension via nebulization

Nafee, Noha; Makled, Shaimaa; Boraie, Nabila

doi:10.1016/j.ejps.2018.10.003

Cited by 52 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Output rate exhibited by nebulizers is directly related to nebulization time; the longer the nebulization time, the lower the output rate. Similar findings of high nebulization time and lower aerosol output rate was also reported in the literature using NLCs formulations (Nafee et al, 2018) as well as other lipid-based formulations (Elhissi et al, 2007, Khan et al, 2020a.…”

Section: Nebulizer Performance Via Deposition Of Bdp In Various Stage...supporting

confidence: 89%

Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers

Khan

Hussein

Houacine

et al. 2021

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Section: Nebulizer Performance Via Deposition Of Bdp In Various Stage...supporting

confidence: 89%

Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers

Khan

Hussein

Houacine

et al. 2021

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…Mannosylated rifampicin loaded NLCs were also developed in order to target alveolar macrophages via recognition by via mannose receptor uptake for treatment of tuberculosis ( Vieira et al 2017 ). Nafee and coworkers developed sildenafil loaded NLCs in order to treat pulmonary hypertension ( Nafee, Makled, and Boraie 2018 ). NLCs proved the superiority above free solution in terms of low incidence of intra-alveolar bleeding and normality of lung tissue parenchyma.…”

Section: Applications Of Nlcsmentioning

confidence: 99%

Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies

Elmowafy

Al‐Sanea

2021

Saudi Pharmaceutical Journal

178

View full text Add to dashboard Cite

NLCs have provoked the incessant impulsion for the development of safe and valuable drug delivery systems owing to their exceptional physicochemical and then biocompatible characteristics. Throughout the earlier period, a lot of studies recounting NLCs based formulations have been noticeably increased. They are binary system which contains both solid and liquid lipids aiming to produce less ordered lipidic core. Their constituents particularly influence the physicochemical properties and effectiveness of the final product. NLCs can be fabricated by different techniques which are classified according to consumed energy. More utilization NLCs is essential due to overcome barriers surrounded by the technological procedure of lipid-based nanocarriers’ formulation and increased information of the core mechanisms of their transport via various routes of administration. They can be used in different applications and by different routes such as oral, cutaneous, ocular and pulmonary. This review article seeks to present an overview on the existing situation of the art of NLCs for future clinics through exposition of their applications which shall foster their lucid use. The reported records evidently demonstrate the promise of NLCs for innovate therapeutic applications in the future.

show abstract

“…Moreover, a relatively high drug concentration was also detected in liver, brain and bones as possible secondary metastatic sites to lung cancer that may be mediated by systemic absorption into circulation from alveolar sites. Another interesting study involved the use of nebulized nanostructured lipid carriers for delivery of sildenafil in treatment of pulmonary arterial hypertension [9]. Normal lung parenchyma and minimal bleeding were observed after pulmonary administration into rats compared with strong intra-alveolar bleeding caused by free sildenafil, thus confirming the safety of inhalable nanocarriers [9].…”

Section: Nanocarriers For Pulmonary Drug Deliverymentioning

confidence: 97%

Welcome to the 2nd Volume of Bioelectronics in Medicine

Bough

2019

Bioelectron. Med.

View full text Add to dashboard Cite

nasal nanomedicine • oral nanomedicine • parenteral nanomedicine • pharmaceutical nanotechnology • pulmonary nanomedicine • transdermal nanomedicine • wound healing Drug delivery research in EgyptNumerous research groups in Egypt are engaged in the development of nanocarriers for advanced drug-delivery applications. This includes the use of nanocarriers for improving the efficacy of different pharmaceutical formulations including oral, parenteral, pulmonary, nasal, transdermal or topical formulations. In this article, we will discuss the research progress of nanocarrier-based drug-delivery systems as well as the diverse applications leveraging pharmaceutical nanotechnology in the most outstanding Egyptian laboratories and research centers. Among the laboratories most contributing to the field of nanomedicine in Egypt, Cancer Nanotechnology Research Laboratory (CNRL) founded in 2014 at Faculty of Pharmacy, Alexandria University is a good representative. The number of patients diagnosed with cancer in Egypt increases every year. Therefore, the CNRL researchers significantly enriched the cancer nanomedicine area with numerous studies, particularly for treatment of lung, breast and liver cancers widely spread in Egypt. Another promising research center is the Nanomedicine Division, Center for

show abstract

Nanostructured lipid carriers versus solid lipid nanoparticles for the potential treatment of pulmonary hypertension via nebulization

Cited by 52 publications

References 52 publications

Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers

Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers

Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies

Welcome to the 2nd Volume of Bioelectronics in Medicine

Contact Info

Product

Resources

About